Navigation Links
Eurand's Zentase Effective in Treating Exocrine Pancreatic,Insufficiency, Studies Show

Zentase Improves Absorption of Fat, Protein and Other Nutrients in Patients with Mild, Moderate or Severe Malabsorption, While Controlling Symptoms of Exocrine Pancreatic Insufficiency

MILAN, Italy and DAYTON, Ohio, June 19, 2007 /PRNewswire-FirstCall/ -- Eurand N.V. today announced results that were presented at the recent European Cystic Fibrosis Society meeting in Antalya, Turkey, held June 13-16. Results from two phase III studies of Zentase(TM) (EUR-1008) showing a statistically and clinically significant improvement in the absorption of fat, protein and nutrients in patients suffering from Exocrine Pancreatic Insufficiency (EPI). Absorption levels were measured by coefficient of fat (CFA) and coefficient of nitrogen (CNA) absorption, common measurements for malabsorption in EPI patients. In the pivotal study, the mean CFA after Zentase was 88.3 percent and the mean CNA after Zentase was 87.2 percent. Levels under placebo were 62.8 and 65.7 percent respectively (p=0.001). Scientific evidence suggests that to normalize EPI, treatment needs to raise CFA levels to at least 85 percent.(1)

The data were the basis for the recent rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zentase as a treatment for EPI. EPI is a potentially lethal disease marked by the deficiency of digestive enzymes normally produced by the pancreas. This deficiency results in poor digestion and reduced absorption of nutrients, which, if left untreated, can lead to malnutrition, impaired growth, weakened immune response, and shortened life expectancy. Treatment with pancreatic enzyme products (PEPs) replaces enzymes lost through the disease. Currently, there are no known alternative therapies to PEPs for EPI.

EPI can occur as a complication of a variety of diseases, including cystic fibrosis, pancreatic cancer, surgery and chronic pancreatitis. There are no reliable statist
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Eurand to Present Zentase Phase III Data
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... The Chinese wound care market is in ... the incidence of lifestyle diseases, coupled with the increase ... better quality of wound care products provide the impetus ... public health insurance schemes and increased reimbursement rate for ... the findings of primary and secondary researches, this research ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), ... for the sale of Gastrodia valued at 67.5 Million ... are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe ... of 550 tons of Gastrodia from January 1, 2012 to December ...
... Accuray Incorporated (Nasdaq: ARAY ), the ... study demonstrating the benefits of the CyberKnife® Robotic ... the treatment of central lung tumors using gantry based ... a great deal of accuracy to avoid risks of ...
Cached Medicine Technology:China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 2Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 4
(Date:9/30/2014)... partnership funded by the Department of Defense (DoD) ... better-run clinical trials and may lead to the ... condition affecting not only athletes and soldiers, but ... youngsters to elders. , Under the partnership, ... million, five-year award from the DoD, the research ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Life Length ... provides CHL access to Life Length’s proprietary Telomere Analysis ... and comprehensive telomere test on the market today, and ... the percentage of short telomeres, providing the most critical ... Chairman of the Department of Cell Biology at The ...
(Date:9/30/2014)... 2014 Market Research Report on ... professional and in-depth market survey on Global and ... basic information of Cialis including its classification, application ... and China’s top manufacturers of Cialis listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
Breaking Medicine News(10 mins):Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3
... HIV case in Libya involving five Bulgarian nurses and a ... that they were tortured brutally to give false testimonies. ... when they were accused of starting an HIV epidemic in ... the infections have begun much before the arrival of these ...
... the better your heart health. But a man’s heart ... relationships among cholesterol levels,// psychological function, and neurologic disorders ... Harvard Men’s Health Watch. ,There are ... disease. Vascular dementia results when blood vessel damage deprives ...
... launched ‘The HumaPen Memoir’ the world's first digital insulin pen ... simplifies the management of diabetic patients who require timely insulin ... designed to meet the needs of people with diabetes who ... ,The unique pen memory device can help the patient to ...
... select patients for further testing may increase detection of ... colorectal cancer at a young age, //researchers report in ... National Cancer Institute. ,Lynch syndrome, also known ... mutations in DNA mismatch repair genes, the genes that ...
... key signaling protein in the brain during infancy could ... //According to findings published today in the journal Nature, ... serotonin just after birth exhibit abnormal anxiety as adults. ... mice genetically engineered to lack the receptor for serotonin, ...
... cases of dengue fever were reported across Paraguay in the ... new //cases a day last week, Paraguay's health authorities said ... has not yet declared the epidemic to be a health ... ,Dengue fever is a viral infection spread by the ...
Cached Medicine News:Health News:Mouse Study Suggests Anxiety Disorders Take Root in Infancy 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: